Observational studyBMC medicine2026
Vericiguat for endothelial dysfunction and CRT response in non-responders: the VERCET prospective observational study.
Observational study in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reversal of Pacing-Induced Cardiomyopathy After Upgrade to Left Bundle Branch Area Pacing: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndothelial dysfunction (ED) is a negative prognostic factor for patients with heart failure (HF) who are treated with cardiac resynchronization therapy (CRT). ED could lead to CRT non-responders by increasing endothelin-1 (ET-1) expression and inflammatory/oxidative stress markers. STUDY HYPOTHESIS: Vericiguat is an anti-HF medication that may reduce inflammatory/oxidative stress, ET-1 expression, and improve endothelial function in ED-CRT non-responders, leading to better outcomes.
methodsWe conducted a prospective observational study enrolling ED-CRT non-responders treated with vericiguat (vericiguat users) versus those who did not receive vericiguat (non-vericiguat users). ED was diagnosed by flow-mediated vasodilation (FMD ≤ 7.1%) of the brachial artery. Clinical, echocardiographic, and biochemical assessments (inflammatory markers and ET-1) were performed at baseline and at 12 months. The primary endpoints were normalization of endothelial function (FMD > 7.1%) and CRT response at 1 year. Secondary endpoints included changes in inflammatory/oxidative stress markers, ET-1 levels, and clinical outcomes (HF hospitalizations, cardiac, and all-cause mortality).
resultsA total of 289 ED-CRT non-responders were included, of whom 81 received vericiguat (vericiguat users) and 208 did not receive vericiguat (nonusers). At 1-year follow-up, vericiguat users vs. non-users demonstrated significant improvement in New York Heart Association class, 6-min walking test, and left ventricular remodeling (p < 0.05). Vericiguat users vs. non-users showed a significant reduction in inflammatory/oxidative stress biomarkers, B-type natriuretic peptide, and ET-1 (p < 0.05). At the end of follow-up, a lower rate of vericiguat users versus nonusers was under treatment with loop diuretics, aldosterone blockers, and sodium-glucose-transporter 2 inhibitors (p < 0.05). At follow-up end, a higher rate of vericiguat users vs. nonusers showed normalization of endothelial function (30 (37%) vs. 21 (10.1%), p < 0.05) and restored CRT responders (28 (34.6%) vs. 27 (13%), p < 0.05). At 1-year follow-up, the normalization of endothelial function was predicted by left-ventricle ejection fraction (0.42, CI 95% [0.02-0.72]) and vericiguat (4.35, CI 95% [2.45-7.70]). The CRT responders' outcome was predicted by vericiguat therapy (2.85, 95% CI [1.67-4.89]).
conclusionsOur findings demonstrate that vericiguat reduces ED and enhances the response to CRT in prior non-responders by significantly lowering inflammatory/oxidative stress markers and ET-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.